Pharmacotherapy of alcohol dependence: A review of the clinical data

CNS Drugs

Volumn 18, Issue 8, 2004, Pages 485-504

  Mann, Karl ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ALCOHOL; AMISULPRIDE; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CALCIUM CARBIMIDE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DESIPRAMINE; DISULFIRAM; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; FLUPENTIXOL; FLUPENTIXOL DECANOATE; LITHIUM; NALMEFENE; NALTREXONE; NEFAZODONE; NEUROLEPTIC AGENT; NEUROPEPTIDE Y; NEUROTRANSMITTER; ONDANSETRON; OPIATE ANTAGONIST; OXYBATE SODIUM; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; TIAPRIDE; TRANQUILIZER; UNINDEXED DRUG;

ALCOHOL ABSTINENCE; ALCOHOLISM; ANXIETY DISORDER; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRINKING BEHAVIOR; DRUG EFFICACY; FATIGUE; HEADACHE; HUMAN; LIVER TOXICITY; MAJOR DEPRESSION; MENTAL DISEASE; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREMOR; VOMITING;

ALCOHOL DETERRENTS; ALCOHOL-RELATED DISORDERS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIMANIC AGENTS; COMORBIDITY; DOPAMINE AGENTS; DRUG THERAPY, COMBINATION; HUMANS; HYPNOTICS AND SEDATIVES; META-ANALYSIS; NARCOTIC ANTAGONISTS; NARCOTICS; NEUROCHEMISTRY; NEUROTRANSMITTER AGENTS; SEROTONIN AGENTS; TREATMENT OUTCOME;

EID: 3042515206     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418080-00002     Document Type: Review

References (118)

1. Maisto SA, Connors GJ, Zywiak WH. Alcohol treatment, changes in coping skills, self-efficacy, and levels of alcohol use and related problems 1 year following treatment initiation. Psychol Addict Behav 2000; 14: 257-66
2. Faingold CL, N'gouemo P, Riaz A. Ethanol and neurotransmitter interactions: from molecular to integrative effects. Prog Neurobiol 1998; 55: 509-35
3. Koob GF, Roberts AJ, Schulteis G, et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 1998; 22: 3-9
4. Spanagel R, Zieglgänsberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 1997; 18: 37-65
5. Samson HH, Harris RA. The neurobiology of alcohol abuse. Trends Pharmacol Sci 1992; 13: 206-11
6. Grobin AC, Matthews DB, Devaud LL, et al. The role of GABAA receptors in the acute and chronic effects of ethanol. Psychopharmacology 1998; 139: 2-19
7. Olds ME, Fobes JL. The central basis of motivation: intracranial self-stimulation studies. Annu Rev Psychol 1981; 32: 523-74
8. Gessa GL, Muntoni F, Collu M, et al. Low doses of ethanol activate dopaminergic neurons in the ventral tegemental area. Brain Res 1985; 348: 201-3
9. Benjamin D, Grant E, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 1993; 621: 137-40
10. Gianoulakis C, Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol Alcohol 1996; 31 Suppl. 1: 33-42
11. Cardoso RA, Brozowski SJ, Chavez-Noriega LE, et al. Effects of ethanol on recombinant human neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther 1999; 289: 774-80
12. Söderpalm B, Ericson M, Olausson P, et al. Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol. Behav Brain Res 2000; 113: 85-96
13. Arendt F. Impairment in memory function and neurodegenerative changes in the cholinergic forebrain system induced by chronic intake of ethanol. J Neural Transm 1994; 44: 173-87
14. Sellers EM, Higgins GA, Sobell MB. 5-HT and alcohol abuse. Trends Pharmacol Sci 1992; 13: 69-75
15. Soubrié P. Reconciling the role of central serotonin neurons in human and animal behavior. Behav Brain Sci 1986; 9: 319-64
16. Modell JG, Glaser FB, Cyr L, et al. Obsessive and compulsive characteristics of craving for alcohol in alcohol abuse and dependence. Alcohol Clin Exp Res 1992; 16: 272-4
17. Anton RF, Moak DH, Latham P. The obsessive compulsive drinking scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behaviour. Alcohol Clin Exp Res 1995; 19: 92-9
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. (DSM-IV). Washington, DC: American Psychiatric Association, 1994
19. Lehert P. Review and discussion of statistical analysis of controlled clinical trials in alcoholism. Alcohol Alcohol Suppl 1993; 2: 157-63
20. Mundle G, Ackermann K, Munkes J, et al. Influence of age, alcohol consumption and abstinence on the sensitivity of carbohydrate-deficient transferrin, gamma-glutamyltransferase and mean corpuscular volume. Alcohol Alcohol 1999; 34: 760-6
21. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 281: 1318-25
22. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 1986; 256: 1449-55
23. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992; 49: 881-7
24. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876-80
25. Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345: 1734-9
26. Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology 1998; 139: 44-52
27. Gastpar M, Bonnet U, Boning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 2002; 22: 592-8
28. Guardia J, Caso C, Arias F, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 2002; 26: 1381-7
29. Kranzler HR, Modesto-Lowe V, Van Kirk JR. Naltrexone vs nefazodone for treatment of alcohol dependence: a placebo-controlled trial. Neuropsychopharmacology 2000; 22: 493-503
30. Chick J, Anton R, Checinski K, et al. A multicentre, randomised, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence in adults. Alcohol Alcohol 2000; 35: 587-93
31. Anton RF, Moak DH, Waid R, et al. Naltrexone and cognitive behavioral therapy of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999; 156: 1758-64
32. Heinälä P, Alho H, Kiianmaa K, et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 2001; 21: 287-92
33. Balldin J, Berglund M, Borg S, et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 2003; 27: 1142-9
34. Monti PM, Rohsenow DJ, Hutchison KE, et al. Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 1999; 23: 1386-94
35. Morris PL, Hopwood M, Whelan G, et al. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 2001; 96: 1565-73
36. Latt NC, Jurd S, Houseman J, et al. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust 2002; 176: 530-4
37. Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997; 54: 737-42
38. Oslin D, Liberto JG, O'Brien J, et al. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 1997; 5: 324-32
39. Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res 1998; 22: 1074-9
40. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60: 92-9
41. McCaul ME, Wand GS, Eissenberg T, et al. Naltrexone alters subjective responses to alcohol in heavy drinking subjects. Neuropsychopharmacology 2000; 22: 480-92
42. Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001; 25: 1634-47
43. Rohsenow DJ, Colby SM, Monti PM, et al. Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res 2000; 24: 1542-9
44. Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol 2001; 36: 2-10
45. Streeton C, Whelan G. Naltrexone, a relapse-prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 2001; 36: 544-52
46. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25: 1335-41
47. Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2000; (3): CD001867
48. O'Malley SS, Jaffe AJ, Chang G, et al. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 1996; 53: 217-24
49. Anton RF, Moak DH, Latham PK, et al. Posttreatment results of combining naltrexone and cognitive behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 2001; 21: 72-7
50. Dahchour A, De Witte P. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol 2000; 60: 343-62
51. Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 2000; 149: 327-44
52. Chick J, Howlett H, Morgan MY, et al. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000; 35: 176-87
53. Lhuintre JP, Moore ND, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 1990; 25: 613-22
54. Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995; 30: 239-47
55. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 347: 1438-42
56. Tempesta E, Janiri L, Bignamini A, et al. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 2000; 35: 202-9
57. Barrias JA, Chabac S, Ferreira L, et al. Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatria Clinica 1997; 18: 149-60
58. Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol 2001; 36: 413-8
59. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate: results from a placebo controlled study in alcohol dependence. Arch Gen Psychiatry 1996; 53: 673-80
60. Geerlings PJ, Ansoms C, Van Der Brink W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 1997; 3: 129-37
61. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 1997; 92: 1537-46
62. Pelc I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. Br J Psychiatry 1997; 170: 73-7
63. Namkoong K, Lee BO, Lee PG, et al. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 2003; 38: 135-41
64. Roussaux JP, Hers D, Ferauge M. Does acamprosate diminish the appetite for alcohol in weaned alcoholics. J Pharm Belg 1996; 51: 65-8
65. Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998; 22: 573-9
66. PeIc I, Le Bon O, Verbanck P, et al. Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients; a placebo controlled double-blind multi-centre study. In: Naranjo C, Sellers E, editors. Novel pharmacological interventions for alcoholism. New York, USA: Springer Verlag, 1992: 348-52
67. Lhuintre JP, Daoust M, Moore ND, et al. Ability of calcium acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1985; I: 1014-6
68. Ladewig D, Knecht T, Lehert P, et al. Acamprosate: a stabilising factor in long-term withdrawal of alcoholic patients. Ther Umsch 1993; 50: 182-8
69. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in maintaining abstinence in alcohol-dependent individuals: results of a meta-analysis. J Stud Alcohol 2004 Jan; 65 (1): 136-9
70. Rubio G, Jiménez-Arriero MA, Ponce G, et al. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol 2001; 36: 419-25
71. Gerra G, Caccavari R, Delsignore R, et al. Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and non-familial alcoholic patients. Curr Ther Res 1992; 52: 291-5
72. Pelc I, Ansoms C, Lehert P, et al. The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modelling of therapy success prediction. Alcohol Clin Exp Res 2002; 26: 1529-38
73. De Wildt WAJM, Schippers GM, Van den Brink W, et al. Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems? Alcohol Alcohol 2002; 4: 375-82
74. Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994; 18: 1162-7
75. Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999; 56: 719-24
76. Mäkelä R, Kallio A, Karhuvaara S, et al. Nalmefene in the treatment of heavy drinkers [abstract]. International Society of Addiction Medicine (ISAM) 2001 Sep 12-14: Trieste 2001
77. Noble EP. Alcoholism and the dopaminergic system: a review. Addict Biol 1996; 1: 333-48
78. Peters DH, Faulds D. Tiapride: a review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 1994; 47: 1010-32
79. Shaw GK, Waller S, Majumdar SK, et al. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 1994; 165: 512-23
80. Shaw GK, Majumdar SK, MacGarvie J, et al. Tiapride in the long-term management of alcoholics of anxious or depressive temperament. Br J Psychiatry 1987; 150: 164-8
81. Wiesbeck GA, Weijers JG, Lesch OM, et al. Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled trial. Alcohol Alcohol 2001; 36: 329-34
82. Marra D, Warot D, Berlin I, et al. Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial. Alcohol Clin Exp Res 2002; 26: 1545-52
83. Linnoila M, Eckardt M, Durcan M, et al. Interactions of serotonin with ethanol: clinical and animal studies. Psychopharmacol Bull 1987; 23: 452-7
84. McGrath PJ, Nunes EV, Stewart JW, et al. Imipramine treatment of alcoholics with major depression. Arch Gen Psychiatry 1996; 53: 232-40
85. Mason BJ, Kocsis JH, Ritvo EC, et al. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996; 275: 761-7
86. Gorelick DA, Paredes A. Effects of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 1992; 16: 261-5
87. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995; 152: 391-7
88. Janiri L, Gobbi G, Manneli P, et al. Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. Int Clin Psychopharmacol 1996; 11: 109-17
89. Kabel DI, Petty F. A placebo-controlled, double-blind study of fluoxetine in severe alcohol-dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res 1996; 20: 780-4
90. Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 700-5
91. Roy A. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry 1998; 44: 633-7
92. Pettinati HM, Volpicelli JR, Luck G, et al. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 2001; 21: 143-53
93. Coşkunol H, Gökden O, Sabri Ercan E, et al. Long-term efficacy of sertraline in the prevention of alcoholic relapses in alcohol-dependent patients: a single-center, double-blind, randomized, placebo-controlled, parallel-group study. Curr Ther Res 2002; 63: 759-71
94. Gual A, Balcells M, Torres M, et al. Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: a randomized controlled trial. Alcohol Alcohol 2003; 38: 619-25
95. Naranjo CA, Bremner KE, Lanctot KA. Effects of citalopram and a brief psychosocial intervention on alcohol intake, dependence and problems. Addiction 1995; 90: 87-99
96. Tiihonen J, Ryynanen DP, Kauhanen J, et al. Citalopram in the treatment of alcoholism. Pharmacopsychiatry 1996; 29: 27-9
97. Johnson BA, Jasinski DR, Galloway GP, et al. Ritanserin in the treatment of alcohol dependence: a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology 1996; 128: 206-15
98. Wiesbeck GA, Weijers JG, Chick J, et al. Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled, double-blind international multicenter trial. Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res 1999; 23: 230-5
99. Sellers EM, Toneatto T, Romach MK, et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994; 18: 879-85
100. Johnson BA, Roace JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomised clinical trial. JAMA 2000; 284: 1016-7
101. Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology 1989; 22: 49-59
102. Tollefson GD, Montague-Clouse J, Tollefson SL. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol 1992; 12: 19-26
103. Malcolm R, Anton RF, Randall CL, et al. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 1992; 16: 1007-13
104. Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry 1994; 51: 720-31
105. Malec TS, Malec EA, Dongier M. Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res 1996; 20: 853-8
106. Malec TS, Malec EA, Gagne MA, et al. Efficacy of buspirone in alcohol dependence: a placebo-controlled trial. Alcohol Clin Exp Res 1996; 20: 309-12
107. Messiha FS, Butler D, Adams MK. Carbamazepine and ethanol elicited responses in rodents. Alcohol 1986; 3: 131-3
108. Alexander GJ, Alexander RB. Alcohol comsumption in rats treated with lithium carbonate or rubidium chloride. Pharmacol Biochem Behav 1978; 8: 533-6
109. Dorus W, Ostrow DG, Anton R, et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA 1989; 262: 1646-52
110. Mueller TI, Stout RL, Rudden S, et al. A double-blind placebo-controlled pilot study of Carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res 1997; 21: 86-91
111. Gallimberti L, Ferri M, Ferrara SD, et al. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res 1992; 16: 673-6
112. Ait-Daoud N, Johnson BA, Prihoda TJ, et al. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology 2001; 154: 23-7
113. Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997; 53: 1038-53
114. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Arch Gen Psychiatry 1997; 54: 1130-5
115. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 1999; 20: 427-35
116. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-8
117. Kessler RC, Crum RM, Warber LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997; 54: 313-21
118. Swift RM. Drug therapy for alcohol dependence. N Engl J Med 1999; 340: 1482-7